503 related articles for article (PubMed ID: 12391241)
61. Improved efficacy of therapeutic vaccination with dendritic cells pulsed with tumor cell lysate against hepatocellular carcinoma by introduction of 2 tandem repeats of microbial HSP70 peptide epitope 407-426 and OK-432.
Ge C; Xing Y; Wang Q; Xiao W; Lu Y; Hu X; Gao Z; Xu M; Ma Y; Cao R; Liu J
Int Immunopharmacol; 2011 Dec; 11(12):2200-7. PubMed ID: 22015603
[TBL] [Abstract][Full Text] [Related]
62. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
Kemp RA; Ronchese F
J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
[TBL] [Abstract][Full Text] [Related]
63. Uncarinic acid C plus IFN-γ generates monocyte-derived dendritic cells and induces a potent Th1 polarization with capacity to migrate.
Bae WK; Umeyama A; Chung IJ; Lee JJ; Takei M
Cell Immunol; 2010; 266(1):104-10. PubMed ID: 20933226
[TBL] [Abstract][Full Text] [Related]
64. Dendritic cell-based combined immunotherapy with autologous tumor-pulsed dendritic cell vaccine and activated T cells for cancer patients: rationale, current progress, and perspectives.
Morisaki T; Matsumoto K; Onishi H; Kuroki H; Baba E; Tasaki A; Kubo M; Nakamura M; Inaba S; Yamaguchi K; Tanaka M; Katano M
Hum Cell; 2003 Dec; 16(4):175-82. PubMed ID: 15147037
[TBL] [Abstract][Full Text] [Related]
65. Linkage of CD40L to a self-tumor antigen enhances the antitumor immune responses of dendritic cell-based treatment.
Chen HW; Huang HI; Lee YP; Chen LL; Liu HK; Cheng ML; Tsai JP; Tao MH; Ting CC
Cancer Immunol Immunother; 2002 Aug; 51(6):341-8. PubMed ID: 12111122
[TBL] [Abstract][Full Text] [Related]
66. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
67. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
68. Mutual helper effect in copulsing of dendritic cells with 2 antigens: a novel approach for improvement of dendritic-based vaccine efficacy against tumors and infectious diseases simultaneously.
Shojaeian J; Jeddi-Tehrani M; Dokouhaki P; Mahmoudi AR; Ghods R; Bozorgmehr M; Nikoo S; Bayat AA; Akhondi MM; Ostadkarampour M; Rezania S; Zarnani AH
J Immunother; 2009 May; 32(4):325-32. PubMed ID: 19342973
[TBL] [Abstract][Full Text] [Related]
69. Antitumor immunity by a dendritic cell vaccine encoding secondary lymphoid chemokine and tumor lysate on murine prostate cancer.
Lu J; Zhang Q; Liang CM; Xia SJ; Zhong CP; Wang DW
Asian J Androl; 2008 Nov; 10(6):883-9. PubMed ID: 18958352
[TBL] [Abstract][Full Text] [Related]
70. Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors.
Osada T; Nagaoka K; Takahara M; Yang XY; Liu CX; Guo H; Roy Choudhury K; Hobeika A; Hartman Z; Morse MA; Lyerly HK
J Immunother; 2015 May; 38(4):155-64. PubMed ID: 25839441
[TBL] [Abstract][Full Text] [Related]
71. Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system.
Wikstrand CJ; Cole VR; Crotty LE; Sampson JH; Bigner DD
Cancer Immunol Immunother; 2002 Feb; 50(12):639-52. PubMed ID: 11862416
[TBL] [Abstract][Full Text] [Related]
72. Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens.
Iranpour S; Nejati V; Delirezh N; Biparva P; Shirian S
J Exp Clin Cancer Res; 2016 Oct; 35(1):168. PubMed ID: 27782834
[TBL] [Abstract][Full Text] [Related]
73. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines.
Kim SK; Ragupathi G; Musselli C; Choi SJ; Park YS; Livingston PO
Vaccine; 1999 Nov; 18(7-8):597-603. PubMed ID: 10547417
[TBL] [Abstract][Full Text] [Related]
74. Immunotherapy of melanoma: a dichotomy in the requirement for IFN-gamma in vaccine-induced antitumor immunity versus adoptive immunotherapy.
Winter H; Hu HM; McClain K; Urba WJ; Fox BA
J Immunol; 2001 Jun; 166(12):7370-80. PubMed ID: 11390488
[TBL] [Abstract][Full Text] [Related]
75. Low molecular weight hyaluronan preconditioning of tumor-pulsed dendritic cells increases their migratory ability and induces immunity against murine colorectal carcinoma.
Alaniz L; Rizzo M; Garcia MG; Piccioni F; Aquino JB; Malvicini M; Atorrasagasti C; Bayo J; Echeverria I; Sarobe P; Mazzolini G
Cancer Immunol Immunother; 2011 Oct; 60(10):1383-95. PubMed ID: 21638126
[TBL] [Abstract][Full Text] [Related]
76. Administration of interleukin-12 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines in mouse hepatocellular carcinoma.
Tatsumi T; Takehara T; Kanto T; Miyagi T; Kuzushita N; Sugimoto Y; Jinushi M; Kasahara A; Sasaki Y; Hori M; Hayashi N
Cancer Res; 2001 Oct; 61(20):7563-7. PubMed ID: 11606395
[TBL] [Abstract][Full Text] [Related]
77. The Improved Antigen Uptake and Presentation of Dendritic Cells Using Cell-Penetrating D-octaarginine-Linked PNVA-co-AA as a Novel Dendritic Cell-Based Vaccine.
Fujioka Y; Ueki H; A R; Sasajima A; Tomono T; Ukawa M; Yagi H; Sakuma S; Kitagawa K; Shirakawa T
Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892182
[TBL] [Abstract][Full Text] [Related]
78. Translational development of active immunotherapy for hematologic malignancies.
Kwak LW
Semin Oncol; 2003 Jun; 30(3 Suppl 8):17-22. PubMed ID: 12881808
[TBL] [Abstract][Full Text] [Related]
79. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model.
Song C; Zheng XJ; Liu CC; Zhou Y; Ye XS
Oncotarget; 2017 Jul; 8(29):47330-47343. PubMed ID: 28537884
[TBL] [Abstract][Full Text] [Related]
80. Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations.
Caspar CB; Levy S; Levy R
Blood; 1997 Nov; 90(9):3699-706. PubMed ID: 9345055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]